Fluvoxamine augmentation in risperidone-resistant schizophrenia: An open trial

Human Psychopharmacology

Volumn 17, Issue 2, 2002, Pages 95-98

  Takashi, Hitoshi ^a   Sugita, Takio ^b   Higuchi, Hisashi ^a   Shimizu, Tetsuo ^a  

^a AKITA UNIVERSITY   (Japan)

^b Yokote Kosei Hospital   (Japan)

Author keywords

Fluvoxamine; Risperidone; Schizophrenia; SSRI augmentation; Treatment resistance

Indexed keywords

BENZODIAZEPINE DERIVATIVE; BIPERIDEN; CHOLINERGIC RECEPTOR BLOCKING AGENT; DIAZEPAM; FLUVOXAMINE; RISPERIDONE; TRIAZOLAM; NEUROLEPTIC AGENT; SEROTONIN UPTAKE INHIBITOR;

ADULT; AKINESIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MALE; MENTAL DISEASE; MUSCLE RIGIDITY; NAUSEA; NEGATIVE SYNDROME; NERVOUSNESS; PARKINSONISM; PRIORITY JOURNAL; RATING SCALE; SCHIZOPHRENIA; SCORING SYSTEM; SWEATING; CHRONIC DISEASE; DRUG COMBINATION; DRUG INTERACTION; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; CHRONIC DISEASE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; FLUVOXAMINE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; SCHIZOPHRENIA; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 0036490550     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/hup.367     Document Type: Article

References (26)

1. Fenfluramine treatment of negative symptoms in older schizophrenic inpatients
2. Combination treatment with clozapine and paroxetine in schizophrenia: Safety and tolerability data from a prospective open clinical trial
3. A pilot study on risperidone metabolism: The role of cytochromes P450 2D6 and 3A
4. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia
5. Fluoxetine augmentation of clozapine treatment in patients with schizophrenia
6. Risperidone in the treatment of negative symptoms of schizophrenia: A meta-analysis
7. Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial
8. Trial of fluoxetine added to neuroleptics for treatment-resistant schizophrenic patients
9. The positive and negative syndrome scale (PANSS) for schizophrenia
10. A double-blind study of adjunctive sertraline in haloperidol-stabilized patients with chronic schizophrenia
11. Risperidone in the treatment of schizophrenia
12. Adverse effects of fenfluramine in treatment refractory schizophrenia
13. Metabolic interactions of central nervous system medications and selective serotonin reuptake inhibitors
14. Citalopram as an adjuvant in chronic schizophrenia: A double-blind placebo-controlled study
15. Treatment of chronic schizophrenia with cyproheptadine
16. Fluvoxamine improves negative symptoms in treated chronic schizophrenia: An add-on double-blind, placebo-controlled study
17. Fluvoxamine augmentation for clozapine-resistant schizophrenia
18. Fluvoxamine augmentation in clozapine-resistant schizophrenia: An open pilot study
19. Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia: Evidence for a specific serotonergic effect from a double-blind study
20. Fluvoxamine augmentation of antipsychotics improves negative symptoms in psychotic chronic schizophrenic patients: A placebo-controlled study
21. A rating scale for extrapyramidal side effects
22. Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients
23. Pilot study on the effects of fenfluramine on negative symptoms in twelve schizophrenic inpatients
24. An open trial of adjunctive sertraline in the treatment of chronic schizophrenia
25. Negative symptoms: A path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine
26. Risperidone in treatment-refractory schizophrenia